Literature DB >> 15785879

The role of B-RAF in melanoma.

Vanessa C Gray-Schopfer1, Silvy da Rocha Dias, Richard Marais.   

Abstract

Melanoma is a form of skin cancer that has a poor prognosis and which is on the rise in Western populations. If detected early, it is easily treated by surgical excision. However, once melanoma metastasises it is notoriously resistant to existing therapies and for many patients the outlook is dismal. Thus a full description of melanoma etiology and a full understanding of the genetic lesions that underlie this disease is required to allow us to develop new and effective therapeutic strategies for its treatment. RAF proteins are a family of serine/threonine-specific protein kinases that form part of a signalling module that regulates cell proliferation, differentiation and survival. In mammals there are three isoforms, A-RAF, B-RAF and C-RAF, and recently it was shown that the B-RAF isoform is mutated in a high proportion of melanomas. In light of these exciting findings, we review what we have learned about B-RAF and its role in cutaneous melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785879     DOI: 10.1007/s10555-005-5865-1

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  39 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Analysis of B-Raf[Formula: see text] inhibitors using 2D and 3D-QSAR, molecular docking and pharmacophore studies.

Authors:  Reza Aalizadeh; Eslam Pourbasheer; Mohammad Reza Ganjali
Journal:  Mol Divers       Date:  2015-08-15       Impact factor: 2.943

Review 3.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

4.  Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Authors:  Victoria Marsh Durban; Marian M Deuker; Marcus W Bosenberg; Wayne Phillips; Martin McMahon
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

Review 5.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

6.  Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.

Authors:  Michael Lidsky; Gamil Antoun; Paul Speicher; Bartley Adams; Ryan Turley; Christi Augustine; Douglas Tyler; Francis Ali-Osman
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

Review 7.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

8.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Authors:  Tiffany J Parmenter; Margarete Kleinschmidt; Kathryn M Kinross; Simon T Bond; Jason Li; Mohan R Kaadige; Aparna Rao; Karen E Sheppard; Willy Hugo; Gulietta M Pupo; Richard B Pearson; Sean L McGee; Georgina V Long; Richard A Scolyer; Helen Rizos; Roger S Lo; Carleen Cullinane; Donald E Ayer; Antoni Ribas; Ricky W Johnstone; Rodney J Hicks; Grant A McArthur
Journal:  Cancer Discov       Date:  2014-01-27       Impact factor: 39.397

9.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

Authors:  Bin Zheng; Joseph H Jeong; John M Asara; Yuan-Ying Yuan; Scott R Granter; Lynda Chin; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

10.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.